19 completed, 4 unknown, 3 recruiting, 2 not yet recruiting. 8 Not applicable, 7 Phase 2, 5 Phase 1, 5 Phase 4, 1 Early Phase 1.
Follow Eye Pain: new trials by email Literature Review of Eye Pain trials Research Report on Eye Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye | Phase 4 | Not yet recruiting | University of South Florida | 28 | 2026-10-01 | 2026-10-06 |
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution - Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | Okyo Pharma Ltd | 111 | 2026-09-01 | 2026-09-29 |
| A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP) Topical Ophthalmic Cooling - Eye Pain | Not applicable | Recruiting | EyeCool Therapeutics, Inc. | 5 | 2025-08-25 | 2026-05-26 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers BL1332 ophthalmic solution, BL1332 ophthalmic vehicle - Ocular Pain | Phase 1 | Active not recruiting | Bausch & Lomb Incorporated | 24 | 2025-07-29 | 2026-01-27 |
| Validation of Ocular Pain Questionnaire: Single-center, Prospective Observational Study Ocular Pain, OSDI | Unknown | IRCCS Ospedale San Raffaele | 333 | 2024-11-01 | 2024-10-24 | |
| Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 Group 1 drug, Group 2: Drug and placebo, Group 3: Drug and palcebo - Ocular Surface Symptom, Ocular Surface Disease | Phase 1 | Unknown | Mohsen Pourazizi | 150 | 2024-10-30 | 2024-10-03 |
| Study of the ETX-4143 2.0 Device in Subjects With Eye Pain ETX-4143 2.0 - Eye Pain | Not applicable | Completed | EyeCool Therapeutics, Inc. | 31 | 2024-08-01 | 2025-08-22 |
| Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration Quantum Molecular Resonance (QMR) Treatment - Neuropathic Corneal Pain | Not applicable | Recruiting | Singapore Eye Research Institute | 30 | 2023-11-01 | 2025-09-19 |
| Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens - Ocular Pain | Early Phase 1 | Completed | Vance Thompson Vision | 10 | 2023-06-26 | 2025-09-17 |
| Alternating and Direct Current Stimulation for Neuropathic Eye Pain DC-Stimulator Plus (NeuroConn GmbH, Germany), Sooma direct current stimulator (Sooma, Finland) - Eye Pain, Neuropathy, Optic | Not applicable | Completed | Neil Lagali | 20 | 2023-06-16 | 2026-07-13 |
| Multisensory Stimulation in Infants for Eye Examination Multisensorial Stimulation - Premature Retinopathy, Pain, Eye | Not applicable | Completed | Akdeniz University | 80 | 2023-06-06 | 2023-12-22 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 50 | 2023-06-01 | 2026-02-20 |
| Pilot Study of TENS for Ocular Pain High frequency forehead TENS, Low frequency forehead TENS - Eye Pain | Not applicable | Completed | VA Office of Research and Development | 39 | 2022-10-03 | 2026-06-10 |
| Cool vs Room-temperature Artificial Tears Refresh Plus Preservative-free Lubricant Eye Drops - Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema | Phase 4 | Completed | University of Iowa | 124 | 2022-03-01 | 2025-03-04 |
| Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) SAF312 Placebo, SAF312 - Chronic Ocular Pain | Phase 2 | Completed | Novartis Pharmaceuticals | 153 | 2021-04-21 | 2024-10-09 |
| A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery Dextenza 0.4Mg Ophthalmic Insert - Anterior Chamber Inflammation, Ocular Pain | Completed | Nicole Fram M.D. | 25 | 2021-03-09 | 2021-07-26 | |
| Effect of Trigeminal Nerve Stimulation on Corneal Nerves and Chronic Ocular Pain Trigeminal Nerve Stimulation - Dry Eye, Neuropathic Pain | Not applicable | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | 7 | 2021-02-03 | 2022-01-18 |
| Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp - Corneal Edema, Corneal Defect | Phase 4 | Completed | Nicole Fram M.D. | 36 | 2020-10-16 | 2023-07-24 |
| DRy Eye Outcome and Prescription Study Artificial tears (classified by MHRA as a medical device) - Dry Eye, Dry Eye Syndrome | Unknown | Guy's and St Thomas' NHS Foundation Trust | 635 | 2018-08-23 | 2018-08-31 | |
| Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. PRO-155, Placebo - Pterygium, Ocular Pain | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 166 | 2017-12-13 | 2019-11-20 |
Showing 20 of 29. Sign in to see all of them.
Dry Eye Syndromes (7) · Corneal Edema (3) · Endophthalmitis (2) · Macular Edema (2) · Neuralgia (2) · Blepharitis (1) · Brain Injuries (1) · Cataract (1) · Corneal Endothelial Cell Loss (1) · Disease (1) · Eye Diseases (1) · Inflammation (1) · Meibomian Gland Dysfunction (1) · Multiple Sclerosis (1)
Eye Manifestations (29) · Neurologic Manifestations (29) · Pain (29) · Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (29) · Eye Diseases (28) · Lacrimal Apparatus Diseases (7) · Corneal Diseases (4) · Nervous System Diseases (4) · Pathologic Processes (3) · Retinal Diseases (3) · Conjunctival Diseases (2) · Cranial Nerve Diseases (2) · Eye Infections (2) · Infections (2)
Calcium Dobesilate (3) · Dexamethasone (2) · bromfenac (2) · prednisolone acetate (2) · Clemastine (1) · Equipment and Supplies (1) · Lubricant Eye Drops (1) · Methylprednisolone (1) · Ophthalmic Solutions (1) · Pharmaceutical Preparations (1) · Therapeutics (1) · omaveloxolone (1)
Nicole Fram M.D. (3) · Sylentis, S.A. (3) · Biogen (2) · EyeCool Therapeutics, Inc. (2) · Novartis Pharmaceuticals (2) · Akdeniz University (1) · Bausch & Lomb Incorporated (1) · Bausch Health Americas, Inc. (1) · Evidence Based Cataract Study Group (1) · Guy's and St Thomas' NHS Foundation Trust (1) · IRCCS Ospedale San Raffaele (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Laboratorios Sophia S.A de C.V. (1) · Mohsen Pourazizi (1) · Neil Lagali (1)
United States (15) · Spain (3) · Australia (2) · Mexico (2) · United Kingdom (2) · China (1) · Estonia (1) · Iran (1) · Japan (1) · Singapore (1) · Sweden (1) · Turkey (Türkiye) (1)
Nicole R Fram, M.D. (2) · Ari Green, MD, MCR (1) · Belen Sadaba, MD, PhD (1) · Denise Ramjit (1) · Douglas Jin, MD (1) · Elizabeth R Felix, PhD (1) · Flavio Mantelli, MD, PhD (1) · Neil Lagali, PhD (1) · Nicole Fram, MD (1) · Patrick R Casey, OD (1) · Pedram Hamrah, MD (1)
PMID 27893109, PMID 36729473, PMID 26305528, PMID 30367938, PMID 41812852, PMID 42101550, PMID 42455250